首页> 外文期刊>Drugs - Real World Outcomes >Using INTERCheck ? to Evaluate the Incidence of Adverse Events and Drug–Drug Interactions in Out- and Inpatients Exposed to Polypharmacy
【24h】

Using INTERCheck ? to Evaluate the Incidence of Adverse Events and Drug–Drug Interactions in Out- and Inpatients Exposed to Polypharmacy

机译:使用InterCheck?评估暴露于多酚腺职系的外分病和住院患者的不良事件和药物 - 药物相互作用的发病率

获取原文
       

摘要

BackgroundPolypharmacy exposes patients with comorbidities (particularly elderly patients) to an increased risk of drug-specific adverse events and drug–drug interactions. These adverse events could be avoided with the use of a computerized prescription support system in the primary care setting. The INTERCheck? software is a prescription support system developed with the aim of balancing the risks and benefits of polytherapy and examining drug–drug interactions.ObjectivesThis observational study used the INTERCheck? software to evaluate the incidence of adverse events and of drug–drug interactions in outpatients and inpatients receiving multiple medications.MethodsPatients were randomly enrolled from the outpatient department ( n =?98) and internal medicine ward ( n =?46) of S. Andrea Hospital of Rome. Polypharmacological treatment was analyzed using INTERCheck? software, and the prevalence of risk indicators and adverse events was compared between the two groups.ResultsPolypharmacy (use of five or more drugs) applied to all except three cases among outpatients and one case among inpatients. A significant positive correlation was found between the number of medications and the INTERCheck? score ( ρ =?0.67; p ?0.000001), and a significant negative correlation was found between the drug-related anticholinergic burden and cognitive impairment ( r =???0.30 p =?0.01). Based on the INTERCheck? analysis, inpatients had a higher score for class D (contraindicated drug combination should be avoided) than did outpatients ( p =?0.01). The potential class D drug–drug interactions were associated with adverse events that caused hospitalization ( χ 2?=?7.428, p =?0.01).ConclusionsINTERCheck? analysis indicated that inpatients had a high risk of drug–drug interactions and a high percentage of related adverse drug events. Further prospective studies are necessary to evaluate whether the INTERCheck? software may help reduce polypharmacy-related adverse events when used in a primary care setting and thus potentially avoid related hospitalization and severe complications such as physical and cognitive decline.
机译:背景PolyPolmaracy将患者(特别是老年患者)暴露于药物特异性不良事件和药物 - 药物相互作用的风险增加。通过在初级保险环境中使用计算机化处方支持系统,可以避免这些不良事件。互核?软件是一种处方支持系统,其目的是平衡多疗法和检查药物 - 药物相互作用的风险和益处。毒物活跃的观察研究使用了InterCheck?软件评估不良事件的发生率和接受多种药物的门诊患者和住院患者的药物 - 药物相互作用。方法从门诊部(n =Δ98)和内科病房(n =Δ46)中随机注册了andrea罗马医院。使用InterCheck分析Polypharcacalicatical治疗?软件,风险指标和不良事件的患病率在两组中比较了两组。结果(使用五种或更多种药物),除了至少三种病例和住院患者中的一种案例。在药物数量和中断之间发现了显着的阳性相关性吗?得分(ρ= 0.67; p <0.000001),在药物相关的抗胆碱能负荷和认知障碍之间发现了显着的负相关(R = ??? 0.30p = 0.01)。基于InterCheck?分析,住院患者对D类(应避免禁忌药物组合)比门诊患者更高(P = 0.01)。潜在的D类药物 - 药物相互作用与导致住院病的不良事件有关(χ2?= 7.428,P = 0.01).ClclusionsInterCheck?分析表明,住院患者具有高风险的药物 - 药物相互作用和高百分比的相关不良药物事件。进一步的前瞻性研究是评估是否是互上检查的必要性研究?当在初级保健环境中使用时,软件可能有助于减少与多药物相关的不良事件,因此可能避免相关住院治疗和严重并发症,如身体和认知下降。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号